Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
D000281:Administration, Intranasal; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis; D002064:Buserelin / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007273:Injections, Intramuscular; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D002064:Buserelin